100490-19-5 Usage
Uses
Used in Pharmaceutical Industry:
1-(2,4-difluorophenyl)-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid is used as an antibiotic agent for the treatment of bacterial infections. Its unique chemical structure and properties provide it with the potential to be a new and effective option in combating resistant bacterial strains.
Used in Research and Development:
In the field of microbiology and pharmaceutical research, 1-(2,4-difluorophenyl)-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid serves as a valuable compound for studying its antimicrobial properties and mechanisms of action. This research can lead to the development of new antibiotics and a better understanding of bacterial resistance.
Used in Clinical Trials:
As a potential new antibiotic, 1-(2,4-difluorophenyl)-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid may be utilized in clinical trials to evaluate its safety, efficacy, and optimal dosage for treating specific bacterial infections. These trials are crucial for determining its suitability as a new therapeutic option in the medical field.
Check Digit Verification of cas no
The CAS Registry Mumber 100490-19-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,4,9 and 0 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 100490-19:
(8*1)+(7*0)+(6*0)+(5*4)+(4*9)+(3*0)+(2*1)+(1*9)=75
75 % 10 = 5
So 100490-19-5 is a valid CAS Registry Number.
100490-19-5Relevant articles and documents
NOVEL METHOD OF SYNTHESIS OF FLUOROQUINOLONES
-
Page/Page column 6; 10-11, (2009/04/24)
The invention relates to a method of preparation of fluoroquinolones of formula (I) from compounds of formula (II): in which R1, R2, R3, R4, R5, R6, R7, and X are as defined in Claim 1.
RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES
-
Page/Page column 38-39, (2010/02/13)
Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.
Naphthyridine antibacterial compounds
-
, (2008/06/13)
Naphthyridine compounds having the formula: STR1 wherein Z is an amine or an aliphatic heterocyclic group, R is a phenyl group or an aromatic heterocyclic group and R1 is hydrogen or a carboxy protecting group. The compounds of the invention ha
